Welltower (WELL) Down 1.2% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Welltower's recent earnings report shows strong performance with significant year-over-year growth in both FFO and revenues, indicating potential for continued positive momentum leading up to the next earnings release [3][4][8]. Financial Performance - Welltower's Q4 2025 normalized FFO per share was $1.45, exceeding the Zacks Consensus Estimate of $1.44, and reflecting a 28.3% increase year over year [3]. - The company reported revenues of $3.18 billion for the quarter, surpassing the Zacks Consensus Estimate of $2.71 billion, marking a 41.3% year-over-year increase [4]. - The same-store revenues in the SHO portfolio increased by 9.6% year over year, supported by a 400 basis-point rise in average occupancy and a 4.7% growth in Revenue per Occupied Room (RevPOR) [5]. Investment and Dispositions - In Q4, Welltower's pro-rata gross investments totaled $13.9 billion, which included $1.2 billion in loan funding and $112 million in development funding [6]. - The company completed pro-rata property dispositions of $6.1 billion and loan repayments of $1.4 billion during the same quarter [6]. Balance Sheet Position - As of December 31, 2025, Welltower had $10.2 billion in available liquidity, consisting of $5.2 billion in cash and restricted cash, along with full capacity under its $5 billion line of credit [7]. 2026 Guidance - Welltower provided guidance for 2026 normalized FFO per share in the range of $6.09 to $6.25, anticipating average blended SSNOI growth of 11.25% to 15.75% across various segments [8]. - The company plans to fund an additional $370 million in development for ongoing projects in 2026 [8]. Market Sentiment - There has been an upward trend in estimates for Welltower over the past month, indicating positive market sentiment [9]. - Welltower currently holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [12]. Industry Comparison - Welltower operates within the Zacks REIT and Equity Trust - Other industry, where competitor Healthpeak (DOC) has seen a 0.7% gain over the past month, with its recent revenue growth at 3.1% year over year [13].